12,015 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by LM Advisors LLC

LM Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 12,015 shares of the biopharmaceutical company's stock, valued at approximately $1,110,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. RFG Advisory LLC lifted its position in Gilead Sciences by 4.4% during the 4th quarter. RFG Advisory LLC now owns 13,910 shares of the biopharmaceutical company's stock worth $1,285,000 after acquiring an additional 581 shares in the last quarter. Moody Lynn & Lieberson LLC boosted its holdings in Gilead Sciences by 334.0% in the 4th quarter. Moody Lynn & Lieberson LLC now owns 21,307 shares of the biopharmaceutical company's stock worth $1,968,000 after acquiring an additional 16,397 shares during the period. First Citizens Bank & Trust Co. grew its position in Gilead Sciences by 1.3% in the fourth quarter. First Citizens Bank & Trust Co. now owns 15,468 shares of the biopharmaceutical company's stock valued at $1,429,000 after acquiring an additional 193 shares in the last quarter. Finally, Jamison Private Wealth Management Inc. raised its stake in shares of Gilead Sciences by 5.8% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 27,957 shares of the biopharmaceutical company's stock valued at $2,582,000 after purchasing an additional 1,521 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,929 shares of company stock valued at $5,644,780 in the last quarter. Insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GILD. Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $2.67 during midday trading on Thursday, hitting $111.11. 5,596,339 shares of the company's stock were exchanged, compared to its average volume of 7,714,402. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market cap of $138.21 billion, a P/E ratio of 300.30, a PEG ratio of 0.71 and a beta of 0.26. The stock's 50 day moving average price is $105.36 and its 200-day moving average price is $100.57. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) EPS. The company's quarterly revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.